Clinical Trials

Conatus announces top-line results from ENCORE-NF phase 2b clinical trial in NASH fibrosis

Conatus Pharmaceuticals has announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and liver fibrosis.

GSK’s anti-BCMA antibody-drug conjugate improves ORR in cancer study

GlaxoSmithKline (GSK) announced that 60% of patients with relapsed / refractory multiple myeloma securing GSK2857916 anti-B-cell maturation antigen (BCMA) antibody-drug conjugate achieved an overall response rate (ORR) in DREAMM-1 study.

Merck KGaA, Pfizer discontinue phase III JAVELIN ovarian PARP 100 trial

Merck KGaA and Pfizer have announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (stage III or stage IV).

Study finds widely used heart drug increases risk of sudden cardiac arrest

A recently conducted study found that a commonly used drug for high blood pressure and angina (chest pain) is associated with increased risk of sudden cardiac arrest.

Biohaven enrolls first patient in phase 3 Spinocerebellar Ataxia clinical trial of Troriluzole

Biohaven Pharmaceutical Holding Company, a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in Spinocerebellar Ataxia (SCA).

Xeris Pharmaceuticals doses first patient in phase 2 trial to assess ready-to-use glucagon

Xeris Pharmaceuticals has now begun dosing patients in a phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes who experience episodes of exercise-induced hypoglycemia (EIH).

Esperion unveils positive human trial results for new cholesterol-lowering drug

Esperion Therapeutics said the phase 3 long-term safety study showed that bempedoic acid has significantly reduced low-density lipoprotein cholesterol (LDL-C), as well as high-sensitivity C-reactive protein (hsCRP).

BioArctic announces start of Phase 1 study of ABBV-0805 for Parkinson’s disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805.

Parkinson’s disease study reveals how cancer drug reduces toxic protein in brain

Researchers at the US-based Georgetown University Medical Center claimed to have understood how a cancer drug functions in the brains of patients with Parkinson’s disease.